Kälin Dana, Becsek Angela, Stürmer Helen, Bachofen Claudia, Siegrist Denise, Jonsdottir Hulda R, Schoster Angelika
Clinic for Equine Internal Medicine, Vetsuisse Faculty, University of Zurich, 8057 Zurich, Switzerland.
Equine Internal Medicine, University Equine Clinic, University of Veterinary Medicine Vienna, 1210 Vienna, Austria.
Vaccines (Basel). 2024 Sep 19;12(9):1074. doi: 10.3390/vaccines12091074.
(1) Background: Horses infected by a tick-borne encephalitis virus (TBEV) can develop clinically apparent infections. In humans, vaccination is the most effective preventive measure, while a vaccine is not available for horses. The objective of this study was to describe the immune response in horses after a TBEV vaccination with a human vaccine. (2) Materials and Methods: Seven healthy horses were randomised to a treatment or a control group in a stratified fashion based on TBEV-IgG concentrations on day -4. The treatment group ( = 4) was intramuscularly vaccinated using an inactivated human TBEV vaccine on days 0 and 28; the control group ( = 3) did not receive an injection. A clinical examination and blood sampling were performed on day -4, 0, 2, 4, 6, 8, 10, 14, 28, 30, 32, 34, 36, 38, 43, 56, 84, and 373. A linear mixed model analysis was used to compare IgG and IgM concentrations, neutralising antibody (nAb) titres, leucocyte count, serum amyloid A (SAA), and fibrinogen and globulin concentrations between the groups and time points. (3) Results: The clinical examination was normal in all horses at all time points. There were no significant changes in SAA, globulin, and fibrinogen concentrations and leucocyte count between the groups or time points (all > 0.05). There was no significant increase in IgG, IgM, or nAb titres in the control group over time (all > 0.05). In the vaccination group, there was a significant increase in IgG concentration and nAb titres after the second vaccination ( < 0.0001). There was no significant increase in IgM antibodies after the TBEV vaccination (all > 0.05). One horse in the vaccination group had an IgM concentration above the laboratory reference on day 10. (4) Conclusions: The human TBEV vaccine did not have side effects when used in healthy horses in this study. A significant rise in TBEV-specific IgG antibodies and nAbs after the second vaccination was observed. However, IgG and nAb titres have been shown to decrease within 1 year after vaccination. The results of this study indicate that a vaccination with a human vaccine only induces a mild rise in IgM antibodies and only in previously naive horses. With no significant changes to inflammatory parameters in the vaccinated horses, it remains unclear whether vaccination with the human vaccine leads to protective immunity.
(1) 背景:感染蜱传脑炎病毒(TBEV)的马匹可出现明显的临床感染。在人类中,接种疫苗是最有效的预防措施,而目前尚无用于马匹的疫苗。本研究的目的是描述马匹接种人用疫苗后对TBEV的免疫反应。(2) 材料与方法:根据第 -4天的TBEV-IgG浓度,将7匹健康马匹分层随机分为治疗组或对照组。治疗组(n = 4)在第0天和第28天肌肉注射人用灭活TBEV疫苗;对照组(n = 3)不接受注射。在第 -4、0、2、4、6、8、10、14、28、30、32、34、36、38、43、56、84和373天进行临床检查和采血。采用线性混合模型分析比较两组和不同时间点之间的IgG和IgM浓度、中和抗体(nAb)滴度、白细胞计数、血清淀粉样蛋白A(SAA)以及纤维蛋白原和球蛋白浓度。(3) 结果:所有马匹在所有时间点的临床检查均正常。两组之间以及不同时间点的SAA、球蛋白和纤维蛋白原浓度及白细胞计数均无显著变化(均P > 0.05)。对照组的IgG、IgM或nAb滴度随时间无显著升高(均P > 0.05)。在接种组中,第二次接种后IgG浓度和nAb滴度显著升高(P < 0.0001)。TBEV疫苗接种后IgM抗体无显著升高(均P > 0.05)。接种组中有一匹马在第10天的IgM浓度高于实验室参考值。(4) 结论:在本研究中,人用TBEV疫苗用于健康马匹时未产生副作用。观察到第二次接种后TBEV特异性IgG抗体和nAb显著升高。然而,IgG和nAb滴度在接种后1年内已显示下降。本研究结果表明,接种人用疫苗仅在先前未接触过的马匹中诱导IgM抗体轻度升高。接种疫苗的马匹炎症参数无显著变化,尚不清楚接种人用疫苗是否能产生保护性免疫。